TY - JOUR
T1 - HDL cholesterol response to GH replacement is associated with common cholesteryl ester transfer protein gene variation (-629C > A) and modified by glucocorticoid treatment
AU - Dullaart, Robin P. F.
AU - van den Berg, Gerrit
AU - van der Knaap, Aafke M.
AU - Dijck-Brouwer, Janneke
AU - Dallinga-Thie, Geesje M.
AU - Zelissen, Peter M. J.
AU - Sluiter, Wim J.
AU - van Beek, Andre P.
PY - 2010/2
Y1 - 2010/2
N2 - Objective: GH replacement lowers total cholesterol and low-density lipoprotein cholesterol (LDL-C) in GH-deficient adults, but effects on high-density lipoprotein (HDL) cholesterol (HDL-C) are variable. Both GH and glucocorticoids decrease cholesteryl ester transfer protein (CETP) activity, which is important in HDL metabolism. We determined the extent to which the changes in HDL-C in response to GH replacement are predicted by the -629C>A CETP promoter polymorphism, and questioned whether this association is modified by concomitant glucocorticoid treatment.Design and methods: A total of 91 GH-deficient adults (63 receiving glucocorticoids) were genotyped for the -629 CETP C>A polymorphism. Fasting serum lipids were measured before and after 1.2 +/- 0.4 years of GH treatment (Genotropin, Pfizer Inc., Stockholm, Sweden).Results: In the whole group, total cholesterol and LDL-C decreased (PConclusions: We suggest a common CETP variant-glucocorticoid treatment interaction concerning the effect of GH replacement on HDL-C. This may explain some of the reported variation in the HDL-C response to GH.
AB - Objective: GH replacement lowers total cholesterol and low-density lipoprotein cholesterol (LDL-C) in GH-deficient adults, but effects on high-density lipoprotein (HDL) cholesterol (HDL-C) are variable. Both GH and glucocorticoids decrease cholesteryl ester transfer protein (CETP) activity, which is important in HDL metabolism. We determined the extent to which the changes in HDL-C in response to GH replacement are predicted by the -629C>A CETP promoter polymorphism, and questioned whether this association is modified by concomitant glucocorticoid treatment.Design and methods: A total of 91 GH-deficient adults (63 receiving glucocorticoids) were genotyped for the -629 CETP C>A polymorphism. Fasting serum lipids were measured before and after 1.2 +/- 0.4 years of GH treatment (Genotropin, Pfizer Inc., Stockholm, Sweden).Results: In the whole group, total cholesterol and LDL-C decreased (PConclusions: We suggest a common CETP variant-glucocorticoid treatment interaction concerning the effect of GH replacement on HDL-C. This may explain some of the reported variation in the HDL-C response to GH.
KW - GROWTH-HORMONE REPLACEMENT
KW - DENSITY-LIPOPROTEIN CHOLESTEROL
KW - APOLIPOPROTEIN-E GENOTYPE
KW - HYPOPITUITARY PATIENTS
KW - DEFICIENT ADULTS
KW - PROMOTER POLYMORPHISM
KW - RHEUMATOID-ARTHRITIS
KW - CARDIOVASCULAR RISK
KW - CORONARY RISK
KW - LIPID-LEVELS
U2 - 10.1530/EJE-09-0742
DO - 10.1530/EJE-09-0742
M3 - Article
SN - 0804-4643
VL - 162
SP - 227
EP - 234
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 2
ER -